Radiation dosimetry of <sup>18</sup>F-AzaFol: A first in-human use of a folate receptor PET tracer.

Détails

Ressource 1Télécharger: 32270313_BIB_E6CC33686BEF.pdf (1908.60 [Ko])
Etat: Public
Version: Final published version
Licence: CC BY 4.0
ID Serval
serval:BIB_E6CC33686BEF
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Institution
Titre
Radiation dosimetry of <sup>18</sup>F-AzaFol: A first in-human use of a folate receptor PET tracer.
Périodique
EJNMMI research
Auteur⸱e⸱s
Gnesin S., Müller J., Burger I.A., Meisel A., Siano M., Früh M., Choschzick M., Müller C., Schibli R., Ametamey S.M., Kaufmann P.A., Treyer V., Prior J.O., Schaefer N.
ISSN
2191-219X (Print)
ISSN-L
2191-219X
Statut éditorial
Publié
Date de publication
08/04/2020
Peer-reviewed
Oui
Volume
10
Numéro
1
Pages
32
Langue
anglais
Notes
Publication types: Journal Article
Publication Status: epublish
Résumé
The folate receptor alpha (FRα) is an interesting target for imaging and therapy of different cancers. We present the first in-human radiation dosimetry and radiation safety results acquired within a prospective, multicentric trial (NCT03242993) evaluating the <sup>18</sup> F-AzaFol (3'-aza-2'-[ <sup>18</sup> F]fluorofolic acid) as the first clinically assessed PET tracer targeting the FRα.
Six eligible patients presented a histologically confirmed adenocarcinoma of the lung with measurable lesions (≥ 10 mm according to RECIST 1.1). TOF-PET images were acquired at 3, 11, 18, 30, 40, 50, and 60 min after the intravenous injection of 327 MBq (range 299-399 MBq) of <sup>18</sup> F-AzaFol to establish dosimetry. Organ absorbed doses (AD), tumor AD, and patient effective doses (E) were assessed using the OLINDA/EXM v.2.0 software and compared with pre-clinical results.
No serious related adverse events were observed. The highest AD were in the liver, the kidneys, the urinary bladder, and the spleen (51.9, 45.8, 39.1, and 35.4 μGy/MBq, respectively). Estimated patient and gender-averaged E were 18.0 ± 2.6 and 19.7 ± 1.4 μSv/MBq, respectively. E in-human exceeded the value of 14.0 μSv/MBq extrapolated from pre-clinical data. Average tumor AD was 34.8 μGy/MBq (range 13.6-60.5 μGy/MBq).
<sup>18</sup> F-Azafol is a PET agent with favorable dosimetric properties and a reasonable radiation dose burden for patients which merits further evaluation to assess its performance.
ClinicalTrial.gov, NCT03242993, posted on August 8, 2017.
Mots-clé
Radiology Nuclear Medicine and imaging, 18F-Azafol, Choroid plexuses, Dosimetry, FOLR1, FRalpha, FRα, Folate receptor, Imaging, Lung cancer, OLINDA/EXM, Positron emission tomography (PET)
Pubmed
Web of science
Open Access
Oui
Création de la notice
21/04/2020 10:18
Dernière modification de la notice
15/01/2021 8:12
Données d'usage